Casgevy Disease Interactions
There are 4 disease interactions with Casgevy (exagamglogene autotemcel).
Exagamglogene (applies to Casgevy) Bone marrow transplantation
Moderate Potential Hazard, Moderate plausibility.
Exagamglogene has not been studied in patients who received allogeneic or autologous hematopoietic stem cell transplants. Treatment with exagamglogene is not recommended in these patients.
Exagamglogene (applies to Casgevy) HIV and Hepatitis infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: HIV Infection, Infectious Hepatitis
Exagamglogene has not been studied in patients with HIV-1, HIV-2, hepatitis B virus (HBV), and hepatitis C virus (HCV) infections. Patients should be screened for these infectious agents before collection of cells for manufacturing. Exagamglogene should not be used in patients with active HIV-1, HIV-2, HBV, or HCV.
Exagamglogene (applies to Casgevy) Liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Exagamglogene has not been studied in patients with hepatic impairment. Patients should be assessed for hepatic impairment to ensure that hematopoietic stem cell transplantation is appropriate.
Exagamglogene (applies to Casgevy) Renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Exagamglogene has not been studied in patients with renal impairment (estimated glomerular filtration rate less than 60 mL/min/1.73 m2). Patients should be assessed for renal impairment prior to treatment to ensure that hematopoietic stem cell transplantation is appropriate.
Casgevy drug interactions
There are 93 drug interactions with Casgevy (exagamglogene autotemcel).
More about Casgevy (exagamglogene autotemcel)
- Casgevy consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.